X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    PAXLOVID, The First Oral COVID-19 Generic, Is WHO-Approved

    Singapore Discovers Novel Diabetic Eye Disease Treatment

    Stem Cell Transplantation May Halt Course of MS Impairment

    Major Government Spending Bill Covers FDA, Research Issues

    Funding of Millions of Pounds Towards Genomics Research

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    First Gene Treatment For Early Bladder Cancer Okayed By FDA

    Hemophilia Gene Therapy Now Backed By European Regulators

    WHO Revises Treatment Recommendations For Drug-Resistant TB

    By 2032, The Alzheimers Treatments Market Will Be $6.8 Bn

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    PAXLOVID, The First Oral COVID-19 Generic, Is WHO-Approved

    Singapore Discovers Novel Diabetic Eye Disease Treatment

    Stem Cell Transplantation May Halt Course of MS Impairment

    Major Government Spending Bill Covers FDA, Research Issues

    Funding of Millions of Pounds Towards Genomics Research

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    First Gene Treatment For Early Bladder Cancer Okayed By FDA

    Hemophilia Gene Therapy Now Backed By European Regulators

    WHO Revises Treatment Recommendations For Drug-Resistant TB

    By 2032, The Alzheimers Treatments Market Will Be $6.8 Bn

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

PAXLOVID, The First Oral COVID-19 Generic, Is WHO-Approved

Content Team by Content Team
27th December 2022
in FDA Approvals, News

The generic version of the COVID-19 oral antiviral therapy candidate nirmatrelvir has been approved by the World Health Organization Prequalification of Medicines Program (WHO PQ), as stated by the Indian pharmaceutical company Hetero.

This is the first prequalification for a generic form of PAXLOVID, an oral antiviral medicine manufactured by Pfizer and designated by the WHO as the best therapeutic option available for high-risk patients. Nirmatrelvir and ritonavir were strongly advised by the WHO for mild and moderate COVID-19 patients who were at the greatest risk of being admitted to the hospital, such as those who were immunosuppressed, elderly, or hadn’t had a vaccine.

Nirmatrelvir 150 mg (2 pills) and ritonavir 100 mg are both included in the combo pack, which Hetero is marketing as NIRMACOM (1 tablet). Only by prescription, it must be started within five days after the onset of symptoms and as soon as COVID-19 has been diagnosed. The production of NIRMACOM will take place at Hetero’s facilities in India.

In order to produce and market a generic version of Pfizer’s COVID-19 oral antiviral therapy candidate, nirmatrelvir, in low- and middle-income nations, Hetero engaged in a non-exclusive voluntary licencing agreement with Medicines Patent Pool.

Previous Post

Singapore Discovers Novel Diabetic Eye Disease Treatment

Related Posts

News

Singapore Discovers Novel Diabetic Eye Disease Treatment

26th December 2022
News

Stem Cell Transplantation May Halt Course of MS Impairment

24th December 2022
News

Major Government Spending Bill Covers FDA, Research Issues

24th December 2022
News

Funding of Millions of Pounds Towards Genomics Research

24th December 2022
Usual Pharma Compliance Issues Noted In FDA Warning Letters
FDA Approvals

First Gene Treatment For Early Bladder Cancer Okayed By FDA

20th December 2022
FDA Approvals

Hemophilia Gene Therapy Now Backed By European Regulators

20th December 2022

Latest News

FDA Approvals

PAXLOVID, The First Oral COVID-19 Generic, Is WHO-Approved

27th December 2022
News

Singapore Discovers Novel Diabetic Eye Disease Treatment

26th December 2022
News

Stem Cell Transplantation May Halt Course of MS Impairment

24th December 2022
News

Major Government Spending Bill Covers FDA, Research Issues

24th December 2022
News

Funding of Millions of Pounds Towards Genomics Research

24th December 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In